drugset
drugset / Trial / NCT03614078

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

NCT03614078 ↗

Phase 2 Completed 92 enrolled PRCL Research Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis

Timeline

Start
2018-09-25
Primary completion
2019-04-29
Completion
2019-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PRCL-02 Unknown — Oral

Indications

psoriasis